Trials / Completed
CompletedNCT00533728
Safety of Soluble Beta-Glucan (SBG) in Treatment of Patients With Non-Hodgkin's Lymphoma
A Phase I Study to Determine the Safety and Effect of Soluble Beta-Glucan (SBG) in Combination With Rituximab and COP/CHOP in Patients With Non'Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Biotec Pharmacon ASA · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety of soluble beta-glucan (SBG) in combination with antibody and chemotherapy treatment in patients with non-Hodgkin-s lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Soluble beta-glucan (SBG) |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-02-01
- Completion
- 2009-03-01
- First posted
- 2007-09-21
- Last updated
- 2009-03-04
Locations
1 site across 1 country: Norway
Source: ClinicalTrials.gov record NCT00533728. Inclusion in this directory is not an endorsement.